395 related articles for article (PubMed ID: 9509293)
1. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Coukell AJ; Markham A
Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Fitton A; McTavish D
Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
[TBL] [Abstract][Full Text] [Related]
3. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Wellington K; Goa KL
Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate.
Kellihan MJ; Mangino PD
Ann Pharmacother; 1992 Oct; 26(10):1262-9. PubMed ID: 1421653
[TBL] [Abstract][Full Text] [Related]
8. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in the treatment of malignant bone disease.
Berenson JR; Lipton A
Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the role of bisphosphonates in metastatic disease.
Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
[TBL] [Abstract][Full Text] [Related]
11. [Biphosphonate therapy in the management of skeletal metastases].
Grauer A; Ziegler R
Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
[TBL] [Abstract][Full Text] [Related]
12. Ibandronate.
Dooley M; Balfour JA
Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
14. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
15. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
16. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
19. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
